23 / 36
n, (%)
Crizotinib
(n=151)
Alectinib
(n=152)
AEs leading to treatment discontinuation
19 (13)
17 (11)
AEs leading to dose reduction
31 (21)
24 (16)
AEs leading to dose interruption
38 (25)
29 (19)
Rates of adverse events leading to dose reduction,
interruption, or discontinuation were lower with alectinib
S. Peters N Engl J Med 2017
ALEX Safety